These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 14592699)

  • 1. The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogs.
    Agersø H; Koechling W; Knutsson M; Hjortkjaer R; Karlsson MO
    Eur J Pharm Sci; 2003 Nov; 20(3):335-40. PubMed ID: 14592699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix.
    Broqua P; Riviere PJ; Conn PM; Rivier JE; Aubert ML; Junien JL
    J Pharmacol Exp Ther; 2002 Apr; 301(1):95-102. PubMed ID: 11907162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
    Steinberg M
    Clin Ther; 2009; 31 Pt 2():2312-31. PubMed ID: 20110043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semi-mechanistic pharmacodynamic modeling for degarelix, a novel gonadotropin releasing hormone (GnRH) blocker.
    Jadhav PR; Agersø H; Tornøe CW; Gobburu JV
    J Pharmacokinet Pharmacodyn; 2006 Oct; 33(5):609-34. PubMed ID: 16967346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetic modeling of a subcutaneous depot for GnRH antagonist degarelix.
    Tornøe CW; Agersø H; Nielsen HA; Madsen H; Jonsson EN
    Pharm Res; 2004 Apr; 21(4):574-84. PubMed ID: 15139513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.
    Ozono S; Ueda T; Hoshi S; Yamaguchi A; Maeda H; Fukuyama Y; Takeda K; Ohashi Y; Tsukamoto T; Naito S; Akaza H
    Jpn J Clin Oncol; 2012 Jun; 42(6):477-84. PubMed ID: 22457321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Gonadotropin-Releasing Hormone Antagonist on Risk of Committing Child Sexual Abuse in Men With Pedophilic Disorder: A Randomized Clinical Trial.
    Landgren V; Malki K; Bottai M; Arver S; Rahm C
    JAMA Psychiatry; 2020 Sep; 77(9):897-905. PubMed ID: 32347899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
    Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Degarelix. More rapid medical castration, nothing more.
    Prescrire Int; 2010 Jun; 19(107):106-8. PubMed ID: 20738032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic/pharmacodynamic modelling of GnRH antagonist degarelix: a comparison of the non-linear mixed-effects programs NONMEM and NLME.
    Tornøe CW; Agersø H; Nielsen HA; Madsen H; Jonsson EN
    J Pharmacokinet Pharmacodyn; 2004 Dec; 31(6):441-61. PubMed ID: 16222784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II.
    Samant MP; Gulyas J; Hong DJ; Croston G; Rivier C; Rivier J
    J Med Chem; 2005 Jul; 48(15):4851-60. PubMed ID: 16033265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
    Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
    BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of histopathological findings at the injection site following degarelix administration.
    Maeda T; Kosaka T; Honda A; Okata U; Hayakawa N; Ito Y; Nagata H; Chen KR; Nakamura S; Oya M
    Support Care Cancer; 2015 May; 23(5):1377-81. PubMed ID: 25358643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.
    Gittelman M; Pommerville PJ; Persson BE; Jensen JK; Olesen TK;
    J Urol; 2008 Nov; 180(5):1986-92. PubMed ID: 18801505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolite profiles of degarelix, a new gonadotropin-releasing hormone receptor antagonist, in rat, dog, and monkey.
    Sonesson A; Koechling W; Stalewski J; Tankó LB; Rasmussen BB
    Drug Metab Dispos; 2011 Oct; 39(10):1895-903. PubMed ID: 21768273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Degarelix: a new approach for the treatment of prostate cancer.
    Persson BE; Kold Olesen T; Jensen JK
    Neuroendocrinology; 2009; 90(3):235-44. PubMed ID: 19602868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing subcutaneous injection of the gonadotropin-releasing hormone receptor antagonist degarelix.
    Barkin J; Burton S; Lambert C
    Can J Urol; 2016 Feb; 23(1):8179-83. PubMed ID: 26892063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study.
    Schröder FH; Tombal B; Miller K; Boccon-Gibod L; Shore ND; Crawford ED; Moul J; Olesen TK; Persson BE
    BJU Int; 2010 Jul; 106(2):182-7. PubMed ID: 19912212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biodegradable microparticles for sustained release of a new GnRH antagonist--part I: Screening commercial PLGA and formulation technologies.
    Schwach G; Oudry N; Delhomme S; Lück M; Lindner H; Gurny R
    Eur J Pharm Biopharm; 2003 Nov; 56(3):327-36. PubMed ID: 14602174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.